biotech
Cell Therapeutics and Novartis Co-Develop Poliglumex Paclitaxel
Filed in archive Corporate and Industrial News , Drugs, Vaccines and Therapeutics by ruth on September 19, 2006
TAXOL: Science and Applications
Cell Therapeutics, Inc. and Novartis will collaborate to co-develop XYOTAX™ (poliglumex paclitaxel), an investigational agent in Phase III for the treatment of non-small cell lung cancer (NSCLC) and other cancers. Xyotax, currently in Phase III clinical trials, is a biologically-enhanced chemotherapeutic that links paclitaxel, the active ingredient in Taxol®, to a biodegradable >polyglutamate polymer.
When bound to the polymer, the chemotherapy is rendered inactive, potentially sparing normal tissue's exposure to high levels of unbound, active chemotherapy and its associated toxicities. Blood vessels in tumor tissue, unlike blood vessels in normal tissue, are porous to molecules like polyglutamate. Once inside the tumor cell, enzymes metabolize the protein polymer, releasing the paclitaxel chemotherapy.

Preclinical studies suggest that XYOTAX is preferentially distributed to tumors due to their leaky blood vessels. Since the drug is trapped within the tumor, these cells are exposed to a significantly higher dose of chemotherapy compared to when standard paclitaxel is used.

More on the financial details of the agreement from CTI's press reelase.

Permalink: Cell Therapeutics and Novartis Co-Develop Poliglumex Paclitaxel
Tags: cancer  paclitaxel  lung+cancer  chemotherapy  biotech  cell+therapeutics  poliglumex+paclitaxel  therapeut 
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/36653
img Addthis img Ask img Blinklist img del.icio.us img Digg img Fark img Facebook img Google img Lycos img Ma.gnolia Add this page to Mister Wong Mr Wong img Netscape img Netvousz img Newsvine img Reddit img StumbleUpon img Slashdot img Tailrank img Technorati img Wink img Yahoo

Vote for Cell Therapeutics and Novartis Co-Develop Poliglumex Paclitaxel:

  • Currently 9.33/10
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
Rating: 9.33 out of 3 vote(s) cast.
 
Subscribe
Share It
Popular posts from our other blogs:
RSSrss
See all blog subscribe options
Google google
What is RSS?
Yahoo! yahoo
Addthis Subscribe using any feed reader!
Bloglines Bloglines
Newsletter

TwitterFollow us on Twitter!